HK1169396A1 - Improved process for the preparation of ambrisentan and novel intermediates thereof - Google Patents

Improved process for the preparation of ambrisentan and novel intermediates thereof

Info

Publication number
HK1169396A1
HK1169396A1 HK12110072.6A HK12110072A HK1169396A1 HK 1169396 A1 HK1169396 A1 HK 1169396A1 HK 12110072 A HK12110072 A HK 12110072A HK 1169396 A1 HK1169396 A1 HK 1169396A1
Authority
HK
Hong Kong
Prior art keywords
ambrisentan
preparation
improved process
novel intermediates
intermediates
Prior art date
Application number
HK12110072.6A
Other languages
English (en)
Inventor
Kaushik Babubhai Sata
Bipin Pandey
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of HK1169396A1 publication Critical patent/HK1169396A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK12110072.6A 2009-07-10 2012-10-11 Improved process for the preparation of ambrisentan and novel intermediates thereof HK1169396A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1626MU2009 2009-07-10
IN2233MU2009 2009-09-25
IN462MU2010 2010-02-19
PCT/IN2010/000464 WO2011004402A2 (en) 2009-07-10 2010-07-12 Improved process for the preparation of ambrisentan and novel intermediates thereof

Publications (1)

Publication Number Publication Date
HK1169396A1 true HK1169396A1 (en) 2013-01-25

Family

ID=43297159

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12110072.6A HK1169396A1 (en) 2009-07-10 2012-10-11 Improved process for the preparation of ambrisentan and novel intermediates thereof
HK14105259.9A HK1192880A1 (zh) 2009-07-10 2012-10-11 安貝生坦製備的改進過程

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK14105259.9A HK1192880A1 (zh) 2009-07-10 2012-10-11 安貝生坦製備的改進過程

Country Status (6)

Country Link
US (1) US8962832B2 (de)
EP (2) EP2451786B1 (de)
JP (1) JP5531097B2 (de)
ES (2) ES2575000T3 (de)
HK (2) HK1169396A1 (de)
WO (1) WO2011004402A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017918A2 (de) * 2008-08-11 2010-02-18 Ratiopharm Gmbh Amorphes ambrisentan
CN102219748B (zh) * 2011-05-04 2014-05-07 天津市医药集团技术发展有限公司 无定型安贝生坦及其制备方法
CN102276536B (zh) 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN102887861B (zh) * 2011-07-18 2015-04-15 天津市医药集团技术发展有限公司 一种安贝生坦新晶型及其制备方法
US20140256004A1 (en) 2011-10-19 2014-09-11 Cipla Limited Process for the Preparation of an Endothelin Receptor Antagonist
CN103420811B (zh) * 2012-05-18 2015-04-15 上海医药工业研究院 用于制备安立生坦的中间体化合物及其制备方法、以及安立生坦的制备
PL2867214T3 (pl) 2012-06-29 2017-02-28 Kern Pharma, S.L. Sposób wytwarzania pochodnych kwasów karboksylowych i ich związków pośrednich
CN103524425A (zh) * 2012-07-04 2014-01-22 天津药物研究院 一种安立生坦的晶型v及其制备方法和应用
WO2014139087A1 (zh) * 2013-03-12 2014-09-18 江苏康缘药业股份有限公司 一种手性2-[(4,6-二甲基嘧啶-2-基)氧基]-3-甲氧基-3,3-二苯基丙酸的消旋化方法
CN104515816B (zh) * 2013-09-29 2016-04-20 天津药物研究院 一种安立生坦原料及制剂有关物质的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
ID25620A (id) * 1997-09-04 2000-10-19 Basf Ag Turunan-turunan asam karboksilat baru, pembuatannya dan penggunaannya sebagai campuran reseptor antagonis et a/et b
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19858779A1 (de) * 1998-12-18 2000-06-21 Basf Ag Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19933164A1 (de) * 1999-07-20 2001-01-25 Basf Ag Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
EP2118073A2 (de) * 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selektive endothelin-typ-a-antagonisten
WO2010017918A2 (de) 2008-08-11 2010-02-18 Ratiopharm Gmbh Amorphes ambrisentan
EP2350024A4 (de) 2008-11-05 2012-03-21 Msn Lab Ltd Verbessertes verfahren zur herstellung von endothelin-rezeptorantagonisten
WO2010091877A2 (en) 2009-02-13 2010-08-19 Ratiopharm Gmbh Process for producing ambrisentan

Also Published As

Publication number Publication date
ES2462065T3 (es) 2014-05-22
WO2011004402A2 (en) 2011-01-13
EP2712865B1 (de) 2016-03-16
JP5531097B2 (ja) 2014-06-25
ES2575000T3 (es) 2016-06-23
US20120184573A1 (en) 2012-07-19
EP2451786B1 (de) 2014-01-22
EP2712865A1 (de) 2014-04-02
HK1192880A1 (zh) 2014-09-05
EP2451786A2 (de) 2012-05-16
WO2011004402A3 (en) 2011-03-10
US8962832B2 (en) 2015-02-24
JP2012532863A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
IL215999A0 (en) Processes for the preparation of rivaroxaban and intermediates thereof
HK1169396A1 (en) Improved process for the preparation of ambrisentan and novel intermediates thereof
EP2240470A4 (de) Verbessertes und neues verfahren zur herstellung von bosentan
ZA201201542B (en) Novel polymorphs of rebaudioside c and methods for making and using the same
EP2444398A4 (de) Neuartige zwischenprodukte aus voriconazol und herstellungsverfahren für voriconazol damit
IL219012A0 (en) Process for the preparation of calcobutrol
HUP1000330A2 (en) Process for the preparation of dronedarone and the novel intermediates
SI2387566T1 (sl) Postopek za pripravo rosuvastatina
EP2526099A4 (de) Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
IL221441A0 (en) Process for preparing entecavir and its intermediates
IL216650A0 (en) Process for the preparation and purification of etravirine and intermediates thereof
PL2528923T3 (pl) Sposób wytwarzania darunawiru i pochodnych darunawiru
IL219913A (en) A process for preparing tapentadol and its intermediates
SI2189442T1 (sl) Postopek in intermediati za pripravo aliskirena
HK1165409A1 (en) Process for the preparation of 1-benzyl-3-hydroxymethyl-1h-indazole and its derivatives and required magnesium intermediates 1--3--1h-
IL223066A (en) A process for taptadol synthesis and its intermediates
EP2576556A4 (de) Verfahren zur synthese von carbonnukleosiden und zwischenprodukten zur verwendung darin
EP2643308A4 (de) Verfahren zur herstellung von taurolidin und seinen zwischenprodukten
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
EG27000A (en) Process for the preparation of ibodutant (MEN15596) and related intermediates
IL220477A (en) A process for making Darunavir and intermediates of Daronavir

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180712